Treatment of Poison-Induced Hepatitis

Immediate Management Steps

Discontinue all potentially hepatotoxic medications immediately upon suspicion of drug-induced hepatitis, retaining only essential medications, as recommended by the American Association for the Study of Liver Diseases 1
Obtain detailed history of all prescription drugs, non-prescription medications, herbal supplements, and dietary products taken over the past year, including timing, dosage, and last dose, according to the American Gastroenterological Association 1, 2
Verify ingredients of all non-prescription medications whenever possible, as suggested by the American Association for the Study of Liver Diseases 1

Administer N-acetylcysteine intravenously as the specific antidote for acetaminophen-induced hepatotoxicity, with a total dosage of 300 mg/kg given as 3 sequential doses over 21 hours, as recommended by the American College of Medical Toxicology 3
For mushroom poisoning (Amanita species), administer penicillin G (300,000 to 1 million units/kg/day IV) and silymarin (30-40 mg/kg/day), despite lack of controlled trial evidence, as suggested by the American Association for the Study of Liver Diseases 1

For Grade 2 Hepatitis (ALT/AST >3-5× ULN or bilirubin >1.5-3× ULN), hold all potentially hepatotoxic treatments and consult gastroenterology or hepatology specialist, as recommended by the American Gastroenterological Association 4, 3
For Grade 3 Hepatitis (ALT/AST >5-20× ULN or bilirubin >3-10× ULN), permanently discontinue the offending agent and consider hospitalization and liver biopsy on a case-by-case basis, as suggested by the American Gastroenterological Association 4
For Grade 4 Hepatitis (ALT/AST >20× ULN or bilirubin >10× ULN or hepatic decompensation), hospitalize immediately and start methylprednisolone 2 mg/kg/day or equivalent with planned 4-6 week taper, as recommended by the American Gastroenterological Association 4, 1

For cholestatic drug-induced liver injury, consider ursodeoxycholic acid (UDCA) 13-15 mg/kg/day, as suggested by the American Association for the Study of Liver Diseases 3

Repeat liver function tests within 7-10 days after drug discontinuation to confirm pattern and assess trend, as recommended by the American College of Gastroenterology 3
Exclude competing etiologies, such as viral hepatitis, autoimmune hepatitis, biliary obstruction, and ischemic hepatitis, as suggested by the American Gastroenterological Association 4, 1

Patients with pre-existing liver disease have a higher risk of drug-induced hepatotoxicity, as noted by the American Association for the Study of Liver Diseases 2
Chronic alcohol users have increased risk even if alcohol is discontinued during treatment, as suggested by the American Association for the Study of Liver Diseases 2
For cirrhotic patients with decompensation, coordinate treatment with transplant center, as recommended by the American Association for the Study of Liver Diseases 5

For patients with Grade 2 Hepatitis (ALT/AST >3-5× ULN or bilirubin >1.5-3× ULN), the American Gastroenterological Association recommends holding all potentially hepatotoxic treatments, consulting a gastroenterology or hepatology specialist, and monitoring closely with repeat testing in 2-5 days 6
For patients with Grade 3 Hepatitis (ALT/AST >5-20× ULN or bilirubin >3-10× ULN), the American Gastroenterological Association recommends permanently discontinuing the offending agent, considering hospitalization and liver biopsy on a case-by-case basis, and initiating workup for competing etiologies 6

Patients with pre-existing liver disease have a higher risk of drug-induced hepatotoxicity, may present with rapid deterioration of liver function, and require close monitoring to enable early detection of first signs of DILI, as recommended by the American Association for the Study of Liver Diseases 7
Cirrhotic patients may have normal ALT values or only mild elevations despite significant liver injury, and the AST:ALT ratio may increase to >1, according to the American Association for the Study of Liver Diseases 7

For hepatocellular pattern with elevated baseline ALT, the American Gastroenterological Association recommends using ALT ≥3× baseline or ≥300 U/L as threshold for suspecting DILI, and interrupting study drug and initiating close monitoring if ALT ≥5× baseline or ≥500 U/L with no change in baseline bilirubin 6

In patients with cirrhotic NASH or advanced liver disease, DILI may present with rapid deterioration of liver function with only mild changes in transaminases, and specific thresholds for patients with elevated baseline ALT include ALT ≥2× baseline with doubling of direct bilirubin or increased INR to >1.5, which requires immediate drug interruption, as recommended by the American Association for the Study of Liver Diseases 6
Close monitoring is essential to enable early detection of first signs of DILI and ensure early discontinuation of the drug, according to the American Association for the Study of Liver Diseases 7